Skip to main content

About the Study

Tuberous Sclerosis Complex (TSC): A study of a drug called Ganaxolone (GNX) to reduce seizures.

This study is for children and adults: • Ages 1 and above • Who have been diagnosed with Tuberous Sclerosis Complex (TSC)-related Epilepsy. • Are able to be in the study for 16-20 weeks. The purpose of this research study is to find out if the study drug Ganaxolone (GNX) is safe and reduces the number of seizures you have when added to standard epilepsy treatment and drug(s).

Interested in learning more?

View Study
Information Flyer

Full Study Name: Marinus GNX-TSC A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy

Investigator

CATEGORIES

Children's Mercy Kansas City   /    Children’s Mercy Research Institute   /    Research Studies and Clinical Trials   /    Research Studies and Clinical Trials Search   /   Tuberous Sclerosis Complex (TSC): A study of a drug called Ganaxolone (GNX) to reduce seizures.